CA-SERVICENOW,-INC.
7.7.2020 13:32:12 CEST | Business Wire | Press release
ServiceNow (NYSE:NOW), the leading digital workflow company that makes work, work better for people, today announced that Paul Smith has joined the company as Senior Vice President and General Manager, EMEA, effective July 7, 2020. Smith joins the company from Salesforce, where he held a number of pan EMEA roles and most recently served as Executive Vice President and UK General Manager.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200707005309/en/
Smith brings to ServiceNow 17 years’ experience in leadership and senior management roles in the technology industry, with a track record in leading sales, go-to-market operations and developing new markets to drive triple digit growth.
“ServiceNow is leading the workflow revolution as companies worldwide transform themselves into modern digital enterprises,” said ServiceNow CEO Bill McDermott. “The best leaders and top talent want to work for companies like ServiceNow, where they can create the future. We are thrilled to have Paul Smith join our team, serve our customers and lead our EMEA region to new heights on our journey to becoming the defining enterprise software company of the 21st century.”
Smith will lead a region that includes many of the company’s most important markets and growth opportunities. ServiceNow’s EMEA revenues grew 32 percent in 2019 over the prior year; EMEA achieved an approximately $1 billion revenue run-rate as of Q1 2020.
“ServiceNow is the workflow leader and one of the most exciting and innovative growth companies in the world,” Smith said. “The pristine nature of the single Now Platform gives ServiceNow that rare combination of scale with agility. It’s this exact blend that customers are demanding of their critical partners as they wrestle with digitally transforming their businesses to navigate the change that is yet to come.”
Smith continued: “There are moments in your life when career defining opportunities present themselves; ServiceNow is one of those for me. The talented workforce and commitment to customer and partner success sets it apart from other global brands. I’m thrilled to join and privileged to have the opportunity to lead the EMEA business during the next phase of growth.”
Smith succeeds Phillip van der Wilt who served in this role from January 2016 to July 2020. During this time, and under van der Wilt’s leadership, the EMEA business grew rapidly and established ServiceNow’s strong foothold across EMEA.
“Many thanks to Philip for his leadership in growing our EMEA region over the past four years and establishing ServiceNow as a strategic partner to many of the world’s leading companies,” said Kevin Haverty, ServiceNow’s Executive Vice President of Worldwide Sales. “With Paul on our team, we are set to continue our momentum and drive the next phase of growth. Paul’s strong experience and exceptional track record across the region will help ensure ServiceNow accelerates our leadership as the partner of choice for C-suite leaders driving digital transformation.”
Smith began his career with Procter and Gamble but soon followed a passion for the technology industry that took him to Microsoft and leadership of a number of innovative start-up businesses. He joined Salesforce in 2012 to lead their EMEA Marketing Cloud business, before going on to lead EMEA Cloud Sales until his appointment as EVP and GM UK&I in February 2019.
About ServiceNow
ServiceNow (NYSE: NOW) is making the world of work, work better for people. Our cloud-based platform and solutions deliver digital workflows that create great experiences and unlock productivity for employees and the enterprise. For more information, visit: www.servicenow.com .
© 2020 ServiceNow, Inc. All rights reserved. ServiceNow, the ServiceNow logo, Now, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries. Other company names, product names, and logos may be trademarks of the respective companies with which they are associated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005309/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
